Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease

Clinical Nephrology

Volumn 64, Issue 5, 2005, Pages 371-377

  Dempster, D W ^a   Rosenstock, J L ^a,b   Schwimmer, J A ^a   Panagopoulos, G ^a   DeVita, M V ^a   Michelis, M F ^a  

^a LENOX HILL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Aspirin; Cardiovascular disease; Hemodialysis; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG UTILIZATION; FEMALE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; URBAN AREA;

EID: 27944496877     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64371     Document Type: Article

References (30)

1. ADA 1997 Aspirin therapy in diabetes. American Diabetes Association. Diabetes Care 20: 1772-1773
2. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324: 71-86
3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK 2004 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110: 282-292
4. Baigent CB, Landray M, Leaper C, Altman P, Armitage J, Baxter A, Cairns S, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CRV, Warkwick G, Wheeler DC 2005 First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484
5. Berger AK, Duval S, Krumholz HM 2003 Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42: 201-208
6. Burch JW, Stanford N, Majerus PW 1978 Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61: 314-319
7. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW 2001 Antithrombotic agents in coronary artery disease. Chest 119: 228S-252S
8. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL 2002 Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 33: 1934-1942
9. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH 2003 An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163: 2006-2010
10. Hayden M, Penone M, Phillips C, Mulrow C 2002 Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med 136: 161-172
11. Himmelfarb J, Nelson S, McMonagle E, Holbrook D, Benoit SE, Michelson AD, Ault K 1998 Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. Am J Kidney Dis 32: 132-138
12. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN 2003 Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321
13. Kong DF 2004 Aspirin in cardiovascular disorders - what is the optimum dose? Am J Cardiovasc Drugs 4: 151-158
14. Lauer MS 2002 Aspirin for the primary prevention of coronary events. N Engl J Med 346: 1468-1474
15. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr 1998 Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906
16. Liu Y, Coresh J, Eustace AJ, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ 2004 Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459
17. National Kidney Foundation 2005 K/DOQI Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45: S1-S45
18. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA 2002 AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106: 388-391
19. Ridker PM, Cook NR, Lee I, Gordon D, Gaziano JM, Mason JE, Hennekens CH, Buring JE 2005 A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304
20. Sanchez Perales MC, Vazquez E, Garcia Cores MJ, Borrego FJ, Perez del Barrio P, Liebana A, Gil JM, Viedma G, Perez Banasco V 2002 Platelet antiaggregation and hemorrhagic risk in hemodialyis. Nefrologia 22: 456-462
21. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW 2002 Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40: 1255-1263
22. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW 2003 Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169
23. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA 2001 AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 38: 1581-1583
24. Sreedhara R, Himmelfarb J, Lazaurs M, Hakim RM 1994 Anit-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 45: 1477-1483
25. Stafford R 2000 Aspirin use is low among United States outpatients with coronary artery disease. Circulation 10: 1097-1101
26. Takeda A, Toda T, Fujii T, Shinohara S, Sasaki S, Matsui N 2005 Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 45: 112-118
27. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC 2002 Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 62: 1799-1805
28. USPSTF 2002 Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136: 157-160
29. US Renal Data System 2005 Excerpts from USRDS 2004 annual data report. Am J Kidney Dis 45: S1-S280
30. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO 2003 Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64: 1455-1461